Followers | 840 |
Posts | 120470 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
Wednesday, August 02, 2017 5:00:04 PM
[Miscellaneous updates from disclosures on 2Q17 CC.]
Copaxone (Glatopa) program
• 2017(?): Expected FDA approval of NVS/MNTA’s 40mg-Copaxone ANDA. On 2/17/17, MNTA reported that the ANDA approval was held up due to an FDA compliance issue at PFE’s fill/finish facility, which NVS/MNTA are using for Glatopa (#msg-128816545). Approval probably can’t happen until PFE fixes all compliance issued at this site.
(Although there are other companies with 40mg-Copaxone ANDAs under FDA review, only NVS/MNTA has received FDA approval for the original 20mg formulation. The 20mg and 40mg formulations are identical except for the concentration of drug in the syringe.)
FoB program
• 4Q17: Submit 351(k) FDA application for Humira FoB, which is designated M923 and is wholly owned by MNTA.
• Timing unknown—probably after 351(k) submission: Out-license or commercial partnership for M923.
• 2H17: Report phase-1 data for Orencia FoB, which is designated M934 is and the lead compound in the 50/50 FoB partnership between MNTA and MYL (#msg-126247535). The phase-1 trial started in Nov 2016 (#msg-126247535).
• 4Q17: CAFC hearing on BMY’s Orencia patent. (MNTA appealed the USPTO’s IPR decision in favor of BMY to the CAFC, which granted expedited review.)
• Late 2017/early 2018: File IND for M710 (the second FoB compound in the MNTTA-MYL partnership) and disclose what the compound is.
Proprietary autoimmune program
• 2H17: Report data from SAD and MAD portions of phase-1 trial of M281, an anti-FcRn mAb wholly owned by MNTA.
• 2H17: Start phase-1 trial of M230, an Fc-receptor compound partnered with CSL (#msg-127656306).
• 2018 Start phase-1 trial of M254, a hyper-sialylated IVIG.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM